Navigation

ExploreAnalysisInvestor RelationsAI AssistantCompareScreener
LoginSign Up FreeSign Up

© 2026 MarketCI. All rights reserved.

HelpPricingPrivacyTerms
AL

ALNY

Market Closed

Alnylam Pharmaceuticals, Inc.

NASDAQHealthcareBiotechnology
US
2.50K employees
CEO: Yvonne L. Greenstreet
Founded: 2004
$165.04
+$0.00(+NaN%)
Market Cap
22.11B
Beta
0.27
52W Range
N/A
Dividend Yield
0.00%
OverviewForecastsFundamentalMarket SentimentValuationOwnership
OverviewForecastsFundamentalMarket SentimentValuationOwnership
Comprehensive Valuation
In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Alnylam's current price aligns closely with its PERT-weighted fair value, indicating fair valuation with minimal implied upside (2.5%). Analyst targets suggest potential for significant price variability, contrasting with conservative DCF and P/E estimates. Strong liquidity and profitability scores reduce downside risk, reflecting a balanced risk/reward profile.
Enhanced Football Field Analysis
Loading comprehensive valuation data...

Fetching multi-methodology valuation ranges...

Explore ALNY

Overview

Key metrics and AI-powered insights

Forecast

Price targets and earnings estimates

Fundamentals

Income, balance sheet and cash flow

Valuation

P/E, DCF and valuation multiples

Ownership

Institutional and insider holdings

Sentiment

Analyst ratings and news sentiment

ALNY in the Healthcare

Large Cap
Healthcare

Browse sector stocks →

Biotechnology

Browse industry stocks →